Full Press Release Details
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress.
IDYA
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
Key Takeaway: IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
Price reaction · baseline $24.93 (2025-08-28 close) · hit after-hours · 6 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
-1.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma